Travere Therapeutics Inc (TVTX) - Net Assets
Based on the latest financial reports, Travere Therapeutics Inc (TVTX) has net assets worth $114.83 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($605.19 Million) and total liabilities ($490.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Travere Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $114.83 Million |
| % of Total Assets | 18.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.99% |
| 10-Year Change | -62.69% |
| Growth Volatility | 122.37 |
Travere Therapeutics Inc - Net Assets Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Travere Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Travere Therapeutics Inc (2010–2025)
The table below shows the annual net assets of Travere Therapeutics Inc from 2010 to 2025. For live valuation and market cap data, see how much is Travere Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $114.83 Million | +94.37% |
| 2024-12-31 | $59.08 Million | -70.58% |
| 2023-12-31 | $200.81 Million | +368.62% |
| 2022-12-31 | $42.85 Million | -85.82% |
| 2021-12-31 | $302.11 Million | +43.04% |
| 2020-12-31 | $211.21 Million | -4.51% |
| 2019-12-31 | $221.20 Million | -30.50% |
| 2018-12-31 | $318.25 Million | +8.57% |
| 2017-12-31 | $293.13 Million | -4.75% |
| 2016-12-31 | $307.77 Million | +2.60% |
| 2015-12-31 | $299.97 Million | +905.28% |
| 2014-12-31 | $-37.25 Million | -103.42% |
| 2013-12-31 | $-18.31 Million | -437.35% |
| 2012-12-31 | $-3.41 Million | -5302.37% |
| 2011-12-31 | $-63.08K | -4.69% |
| 2010-12-31 | $-60.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Travere Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 147259174400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.01% |
| Other Comprehensive Income | $-1.19 Million | -1.04% |
| Other Components | $1.59 Billion | 1383.57% |
| Total Equity | $114.83 Million | 100.00% |
Travere Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Travere Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Schneider National Inc
NYSE:SNDR
|
$2.90 Billion |
|
Xiamen Leading Optics Co Ltd
SHG:605118
|
$2.90 Billion |
|
Kyndryl Holdings Inc
NYSE:KD
|
$2.90 Billion |
|
Browave
TWO:3163
|
$2.91 Billion |
|
Lisi S.A
PA:FII
|
$2.90 Billion |
|
Arcplus Group PLC
SHG:600629
|
$2.90 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
$2.90 Billion |
|
FB Financial Corp
NYSE:FBK
|
$2.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Travere Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 59,077,000 to 114,828,000, a change of 55,751,000 (94.4%).
- Net loss of 50,261,000 reduced equity.
- Other comprehensive income decreased equity by 1,109,000.
- Other factors increased equity by 107,121,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.26 Million | -43.77% |
| Other Comprehensive Income | $-1.11 Million | -0.97% |
| Other Changes | $107.12 Million | +93.29% |
| Total Change | $- | 94.37% |
Book Value vs Market Value Analysis
This analysis compares Travere Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.00 | $44.12 | x |
| 2011-12-31 | $-0.59 | $44.12 | x |
| 2012-12-31 | $-31.94 | $44.12 | x |
| 2013-12-31 | $-1.29 | $44.12 | x |
| 2014-12-31 | $-1.49 | $44.12 | x |
| 2015-12-31 | $7.98 | $44.12 | x |
| 2016-12-31 | $8.04 | $44.12 | x |
| 2017-12-31 | $7.56 | $44.12 | x |
| 2018-12-31 | $7.87 | $44.12 | x |
| 2019-12-31 | $5.22 | $44.12 | x |
| 2020-12-31 | $4.44 | $44.12 | x |
| 2021-12-31 | $5.05 | $44.12 | x |
| 2022-12-31 | $0.67 | $44.12 | x |
| 2023-12-31 | $2.70 | $44.12 | x |
| 2024-12-31 | $0.75 | $44.12 | x |
| 2025-12-31 | $1.29 | $44.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Travere Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.24%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 5.27x
- Recent ROE (-43.77%) is above the historical average (-95.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.24K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.52K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.00 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.99 Million |
| 2014 | 0.00% | -393.35% | 0.21x | 0.00x | $-107.21 Million |
| 2015 | 39.08% | 117.36% | 0.19x | 1.71x | $87.24 Million |
| 2016 | -15.56% | -35.86% | 0.25x | 1.71x | $-78.68 Million |
| 2017 | -20.38% | -38.55% | 0.30x | 1.78x | $-89.04 Million |
| 2018 | -32.26% | -62.51% | 0.23x | 2.23x | $-134.50 Million |
| 2019 | -66.20% | -83.51% | 0.29x | 2.73x | $-168.55 Million |
| 2020 | -80.22% | -85.43% | 0.33x | 2.88x | $-190.55 Million |
| 2021 | -59.61% | -136.60% | 0.17x | 2.57x | $-210.30 Million |
| 2022 | -649.88% | -254.41% | 0.16x | 15.70x | $-282.77 Million |
| 2023 | -55.47% | -76.70% | 0.18x | 3.93x | $-131.48 Million |
| 2024 | -544.28% | -137.90% | 0.39x | 10.06x | $-327.45 Million |
| 2025 | -43.77% | -10.24% | 0.81x | 5.27x | $-61.74 Million |
Industry Comparison
This section compares Travere Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Travere Therapeutics Inc (TVTX) | $114.83 Million | 0.00% | 4.27x | $2.90 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more